Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06268236

Electro-acupuncture to Treat Disorder of Consciousness

With the rapid development of life support technology, more and more people can survive severe brain injury. Some survivors regain consciousness after a period of coma, however, many patients develop prolonged disorders of consciousness (DOC), which poses a therapeutic challenge for clinicians and a heavy burden for their families. The investigators design an Electro-acupuncture to treat disorder of consciousness (AcuDoc) trial with the aim of validating the clinical effect of electroacupuncture in treating DOC and exploring its therapeutic mechanisms by integrating EEG, neuroimaging, evoked potential tests, and behavioral assessments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangzhou, Guangdong, 510120, China

Location status: Recruiting

Location contact

Fang Yuan, PhD

CONTACT

[email protected]

+86-20-81887233

About this study

The AcuDoc trial is a single-center, prospective, triple masking, randomized, sham electroacupuncture-controlled study. A total of 50 adult patients with DOC and 25 healthy subjects will be enrolled in the study . Patients will be randomized into electroacupuncture (EA) group or sham EA group (1:1). All patients will receive EA or sham-EA treatment in the supine position at 9 am for 30 minutes once a day for consecutive 14 days and healthy subjects will receive no treatments. The primary objective is to determine the therapeutic benefit of electroacupuncture on the recovery of consciousness in patients with DOC after a 2-week intervention. Key secondary objective is to investigate the effect of electroacupuncture on the circuitry of consciousness using a multimodal approach integrating EEG, neuroimaging (rs-fMRI, amide proton transfer imaging, intravoxel incoherent motion imaging, neurite orientation dispersion and density imaging), and evoked potentials (SEP, BAEP). Other secondary outcomes include the effect of EA on the assessment of brain-computer interface after a 2-week intervention and on the Glasgow Outcome Scale-Extended score at 30 days and 90 days .

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years;
  • With cerebral damage due to TBI;
  • Diagnosed with UWS or MCS based on at least two CRS-R assessments;
  • From 4 to 16 weeks from the onset of brain injury;
  • Informed consent obtained.

Exclusion criteria

  • With a history of neurological or psychiatric disorder prior to the brain injury;
  • With uncontrolled seizures or status epilepticus;
  • Unstable vital signs and requiring the use of vasoactive agents;
  • With the use of general anesthetics or central acting sedative;
  • Without intact skin at acupoints or sham points;
  • Concomitant medical illness that would interfere with the outcome assessments and/or follow-up
  • Pregnant patients;
  • Currently participating in other investigational trials;
  • High likelihood of not adhering to the study treatment or the follow-up regimen

Treatment and study plan

electroacupuncture

Other

Electro-acupuncture at Shuigou and Yintang.

Sham electroacupuncture

Other

Sham-EA at sham-Shuigou and sham-Yintang.

Primary outcomes

  1. Coma Recovery Scale - Revised score

    Time frame: after 14 days of EA or sham-EA treatment

    0 - 23, a higher score indicates a better level of consciousness

Secondary outcomes

  1. phase locking value

    Time frame: after 14 days of EA or sham-EA treatment

    measured by electroencephalogram

  2. amplitude of low-frequency fluctuation

    Time frame: after 14 days of EA or sham-EA treatment

    measured by resting-state functional magnetic resonance imaging

  3. Amide proton transfer-weighted signal

    Time frame: after 14 days of EA or sham-EA treatment

    measured by amide proton transfer imaging

  4. f value

    Time frame: after 14 days of EA or sham-EA treatment

    measured by intravoxel incoherent motion imaging

  5. neurite density index

    Time frame: after 14 days of EA or sham-EA treatment

    measured by neurite orientation dispersion and density imaging

  6. latency value of N20

    Time frame: after 14 days of EA or sham-EA treatment

    measured by somatosensory evoked potential biomarkers

  7. latency between III and V potentials

    Time frame: after 14 days of EA or sham-EA treatment

    measured by brainstem auditory evoked potential

  8. Glasgow Outcome Scale-Extended score

    Time frame: 30 days after randomization

    1 - 8, a higher score indicates better functional recovery from brain injury

  9. Glasgow Outcome Scale-Extended score

    Time frame: 90 days after randomization

    1 - 8, a higher score indicates better functional recovery from brain injury

  10. brain-computer interface accuracy

    Time frame: after 14 days of EA or sham-EA treatment

    measured by electroencephalogram-based brain-computer interface experiment

Study contacts

Contact information is provided by the study sponsor or research team.

Fang Yuan, PhD

CONTACT

[email protected]

+86-20-81887233

Jixiang Chen, PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Feb 20, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.